Preclinical evaluation of the orally active camptothecin analog, RFS-2000 (9-nitro-20(S)-camptothecin) as a radiation enhancer

This publication has 19 references indexed in Scilit:

• A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer
  Anti-Cancer Drugs, 1999
• SN-38, a metabolite of the camptothecin derivative CPT-11, potentiates the cytotoxic effect of radiation in human colon adenocarcinoma cells grown as spheroids
  Radiotherapy and Oncology, 1997
• Enhancement of Tumor Radio‐response by Irinotecan in Human Lung Tumor Xenografts
  Japanese Journal of Cancer Research, 1997
• Phase I Clinical and Pharmacological Studies of 20‐(S)‐Camptothecin and 20‐(S)‐9‐Nitrocamptothecin as Anticancer Agents
  Annals of the New York Academy of Sciences, 1996
• Radiation Enhancement by 9‐Aminocamptothecin
  Annals of the New York Academy of Sciences, 1996
• Radiation lethality enhancement with 9-aminocamptothecin: Comparison to other topoisomerase I inhibitors
  International Journal of Radiation Oncology*Biology*Physics, 1996
• Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells
  International Journal of Radiation Oncology*Biology*Physics, 1992
• Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I
  International Journal of Radiation Oncology*Biology*Physics, 1992
• The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase
  British Journal of Cancer, 1990
• Inhibition of radiation-induced neoplastic transformation by beta-lapachone.
  Proceedings of the National Academy of Sciences, 1989